Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

100.82USD
26 May 2015
Change (% chg)

$-0.53 (-0.52%)
Prev Close
$101.35
Open
$101.19
Day's High
$101.54
Day's Low
$100.58
Volume
2,364,317
Avg. Vol
2,456,134
52-wk High
$109.49
52-wk Low
$95.10

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $279,578.41
Shares Outstanding(Mil.): 2,773.04
Dividend: 0.75
Yield (%): 2.98

Financials

  JNJ.N Industry Sector
P/E (TTM): 18.05 37.10 39.11
EPS (TTM): 5.59 -- --
ROI: 14.86 16.22 15.56
ROE: 22.04 16.99 16.57
Search Stocks

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019

May 20 - U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

CORRECTED-UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19)

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

20 May 2015

Achillion partners with J&J to develop hepatitis C drugs

- Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

19 May 2015

UPDATE 1-Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

19 May 2015

Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market one or more of its hepatitis C drugs.

19 May 2015

FDA approves longer-acting version of J&J's schizophrenia drug

May 19 - The U.S. Food and Drug Administration approved a longer-acting version of Johnson & Johnson's schizophrenia treatment, developed by the company's Janssen Pharmaceuticals unit.

19 May 2015

FDA warns on newer class of type 2 diabetes drugs

- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

15 May 2015

UPDATE 2-U.S. FDA warns on newer class of type 2 diabetes drugs

May 15 - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

15 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: Pechala's Reports
$1,000.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks